{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:22Z","timestamp":1761870382131,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.3816\/clml.2010.n.054","type":"journal-article","created":{"date-parts":[[2010,8,14]],"date-time":"2010-08-14T06:11:22Z","timestamp":1281766282000},"page":"258-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Yttrium-90 Ibritumomab Tiuxetan as a Single Agent in Patients With Pretreated B-Cell Lymphoma: Evaluation of the Long-Term Outcome"],"prefix":"10.3816","volume":"10","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Gandolfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariapaola","family":"Fina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Carlo","family":"Montini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.054_bib1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"year":"2000","series-title":"World Health Organization Classification of Tumours. Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe","key":"10.3816\/CLML.2010.n.054_bib2"},{"key":"10.3816\/CLML.2010.n.054_bib3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ejca.2007.12.008","article-title":"Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop","volume":"44","author":"Zinzani","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLML.2010.n.054_bib4","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin`s lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.3816\/CLML.2010.n.054_bib5","unstructured":"Bartlett NL. 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL) patients. Presented at: the 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, FL. Abstract 51"},{"key":"10.3816\/CLML.2010.n.054_bib6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study form a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.054_bib7","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.054_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3816\/CLM.2006.n.048","article-title":"Salvage chemotherapy in follicular non-Hodgkin's lymphoma: focus on tolerability","volume":"7","author":"Zinzani","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.054_bib9","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomised controlled trials of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus riruximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.054_bib10","first-page":"58","article-title":"Radiolabeled antibody therapy of B-cell lymphomas","volume":"26","author":"Press","year":"1999","journal-title":"Semin Oncol"},{"key":"10.3816\/CLML.2010.n.054_bib11","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","article-title":"Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation","volume":"63","author":"Anderson","year":"1984","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.054_bib12","first-page":"1017","article-title":"Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma","volume":"15","author":"Chinn","year":"1999","journal-title":"Int J Oncol"},{"key":"10.3816\/CLML.2010.n.054_bib13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijrobp.2005.01.017","article-title":"Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy","volume":"63","author":"Gokhale","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.3816\/CLML.2010.n.054_bib14","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.054_bib15","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with Yttrium 90 Ibritumomab Tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.054_bib16","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.054_bib17","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.054_bib18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190500376076","article-title":"Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma","volume":"47","author":"Emmanouilides","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLML.2010.n.054_bib19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1349-7006.2008.00999.x","article-title":"Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma","volume":"100","author":"Tobinai","year":"2009","journal-title":"Cancer Sci"},{"key":"10.3816\/CLML.2010.n.054_bib20","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.054_bib21","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group [erratum in: J Clin Oncol 2000; 18:2351]","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.054_bib22","first-page":"305","article-title":"Aiming at a curative strategy for follicular lymphoma","volume":"58","author":"Bendandi","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CLML.2010.n.054_bib23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.semnuclmed.2003.11.003","article-title":"Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician","volume":"34","author":"Conti","year":"2004","journal-title":"Semin Nucl Med"},{"key":"10.3816\/CLML.2010.n.054_bib24","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4049\/jimmunol.135.2.973","article-title":"The B cell surface molecule B1 is functionally linked with B cell activation and differentiation","volume":"135","author":"Tedder","year":"1985","journal-title":"J Immunol"},{"key":"10.3816\/CLML.2010.n.054_bib25","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/biot.200700043","article-title":"Yttrium 90 ibritumomab tiuxetan (Zevalin): A new bullet in the fight against malignant lymphoma?","volume":"2","author":"Chapuy","year":"2007","journal-title":"Biotechnol J"},{"key":"10.3816\/CLML.2010.n.054_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3960\/jslrt.47.43","article-title":"Radioimmunotherapy for non-hodgkin lymphoma: Historical prospective and current status","volume":"47","author":"Emmanouilides","year":"2007","journal-title":"J Clin Exp Hematop"},{"key":"10.3816\/CLML.2010.n.054_bib27","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1182\/blood.V87.9.3640.bloodjournal8793640","article-title":"Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies","volume":"87","author":"White","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.054_bib28","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase II trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.054_bib29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(08)70039-1","article-title":"Fludarabine and mitoxantrone followed by yttium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)","volume":"9","author":"Zinzani","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.3816\/CLML.2010.n.054_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3816\/CLM.2009.n.044","article-title":"Rituximab plus short-duration chemotherapy followed by Yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"9","author":"Hainsworth","year":"2009","journal-title":"Clin Lymphoma Myeloma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:29Z","timestamp":1761870149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011700313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S2152265011700313"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.054","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yttrium-90 Ibritumomab Tiuxetan as a Single Agent in Patients With Pretreated B-Cell Lymphoma: Evaluation of the Long-Term Outcome","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}